2018
Usefulness of a Simple Algorithm to Identify Hypertensive Patients Who Benefit from Intensive Blood Pressure Lowering
Wang S, Khera R, Das SR, Vigen R, Wang T, Luo X, Lu R, Zhan X, Xiao G, Vongpatanasin W, Xie Y. Usefulness of a Simple Algorithm to Identify Hypertensive Patients Who Benefit from Intensive Blood Pressure Lowering. The American Journal Of Cardiology 2018, 122: 248-254. PMID: 29880288, DOI: 10.1016/j.amjcard.2018.03.361.Peer-Reviewed Original ResearchConceptsSystolic Blood Pressure Intervention TrialIntensive BP loweringUrinary albumin-creatinine ratioFavorable risk-benefit profileAlbumin-creatinine ratioBP loweringRisk-benefit profileHypertensive patientsBlood pressureMajor adverse cardiovascular event ratesAdverse cardiovascular event ratesIntensive blood pressure loweringMajor adverse cardiovascular eventsRemaining low-risk patientsSimple risk prediction modelIntensive blood pressureStandard BP loweringAdverse cardiovascular eventsBlood pressure loweringSerious adverse eventsCardiovascular event ratesLarge randomized trialsLow-risk patientsSubset of patientsCardiovascular disease risk
2012
Impact of Routine Angiographic Follow-Up After Percutaneous Coronary Intervention With Drug-Eluting Stents in the SPIRIT III Randomized Trial at Three Years
Lansky AJ, Brar SS, Yaqub M, Sood P, Applegate RJ, Lazar D, Jankovic I, Hermiller JB, Koo K, Sudhir K, Stone GW. Impact of Routine Angiographic Follow-Up After Percutaneous Coronary Intervention With Drug-Eluting Stents in the SPIRIT III Randomized Trial at Three Years. The American Journal Of Cardiology 2012, 110: 21-29. PMID: 22464212, DOI: 10.1016/j.amjcard.2012.02.040.Peer-Reviewed Original ResearchMeSH KeywordsAngioplasty, Balloon, CoronaryAntineoplastic Agents, PhytogenicCoronary AngiographyCoronary Artery DiseaseEverolimusFollow-Up StudiesHumansImmunosuppressive AgentsPaclitaxelProspective StudiesProsthesis DesignReproducibility of ResultsSingle-Blind MethodSirolimusTime FactorsTreatment OutcomeConceptsPaclitaxel-eluting stentsID-TLRAngiographic groupClinical followMajor adverse cardiovascular event ratesAdverse cardiovascular event ratesDrug-eluting stent placementMajor adverse cardiovascular eventsBare metal stent implantationSPIRIT IIILandmark survival analysisSPIRIT III trialAdverse cardiovascular eventsSafety end pointCardiovascular event ratesIschemia-driven revascularizationMajor clinical outcomesPercutaneous coronary interventionDrug-eluting stentsRoutine AngiographicCardiovascular eventsCoronary revascularizationRevascularization ratesCoronary interventionIII trials
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply